SICKLE CELL DISEASE
&
ITS COMPLICATIONS
(COMPLETE INFO. PPT)
Dr. Armaan Singh
CASE
 A 20 years old male reported with history of
delayed puberty, decreased growth, severe joint
pain, severe weakness and cough. He also have
defective vision
 Past history reveals episodes of jaundice, severe
body aches and pains, and gall stones
 In his childhood he used to have frequently fever
swelling of the hands and feet and pain in the
chest, abdomen, limbs, and joints and nosebleeds
and frequent upper respiratory infections
feb,17,2015
2
Dr.ArmaanSingh
CASE
 O/E; Decreased growth, delayed signs of puberty
severely anemic, mildly jaundiced, ulcers on right leg,
inflamed gums
 Enlarged spleen.
 Temp 39.1°C, diaphoretic, and uncomfortable.
 HR of 90, BP 116/84 mm Hg, RR 26
 O2 Sat 89% and improved to 94% with 6 L/min
via face mask.
 Family history: similar problem in one of his cousin
who died at the age of 30, who used to receive blood
transfusions
feb,17,2015
3
Dr.ArmaanSingh
CASE
 WBC of 17 500/μL
 62% neutrophils
 25% lymphocytes
 9% monocytes
 2% eosinophils
 1% basophils
 1% atypical lymphocytes.
 Hb was 8 g/dL
 reticulocyte 25%
 platelet 206 000/μL.
feb,17,2015
4
Dr.ArmaanSingh
CASE
 Which lab test you will advise?
 What is most probable cause of patients problem?
 What complications the patient may have?
 Design therapeutic objectives for this patient?
feb,17,2015
5
Dr.ArmaanSingh
feb,17,2015
6
Dr.ArmaanSingh
HEMOGLOBIN: INTRODUCTION
 Normal: alpha gene at Chr 16, beta at Chr.11
 HbA: 2 Alfa + 2 beta97-98%
 Hb A2: 2 Alfa + 2 delta 2-3%
 Hb F; 2 alfa + 2 gamma >1%
 Hb S: Glutamic acid at 6 in beta chain replaced with Valine
 HbC:
……………………………………………………………………….Lysine
 Thalassemia:
 Thalassemia describes a group of inherited disorders
characterized by reduced or absent amounts of hemoglobin
 Alfa: less alfa chain Chr.16
 Beta: Chr.11: less beta, beta thalassemia minor
or no beta, all alfa chain beta thalassemia major :
feb,17,2015
7
Dr.ArmaanSingh
 An autosomal recessive genetic disease of Hb synthesis
 Result of a single–amino acid substitution in the β-
globin chain of the Hb molecule, valine for glutamate
at position 6
 Sickle cell trait: Pt. with hetrozygous genotype
 Epidemiology in KSA:
 “The prevalence of SCD in Saudi Arabia varies significantly
in different parts of the country, with the highest prevalence
is in the Eastern province, followed by the southwestern
provinces. The reported prevalence for sickle-cell trait
ranges from 2% to 27%, and up to 2.6% will have SCD in
some areas”
 Ann Saudi Med. 2011 May-Jun; 31(3): 289–293.
feb,17,2015
8
Dr.ArmaanSingh
SICKLE CELL DISEASE
COMPARISON WITH USA
 African Americans:
 SCD: 0.3% Saudia: 2.6%
 SCT: 8.0% Saudia: 2-27%
feb,17,2015
9
Dr.ArmaanSingh
feb,17,2015
10
Dr.ArmaanSingh
feb,17,2015
11
Dr.ArmaanSingh
feb,17,2015
12
Dr.ArmaanSingh
feb,17,2015
13
Dr.ArmaanSingh
PATHOPHYSIOLOGY
 Normal Hemoglobin A: two alpha and two beta chains, 96-97%
 Glutamic acid is on the 6th position of the Beta chain
 Hemoglobin S: Chr.11
 Due to a one point mutation, glutamic acid is replaced by valine at
position 6 in beta chain
 HbS: during deoxygenation
 Polymerize
 Crystellize
 in RBC’s…………………….leading to………………….. Sickling of Cells:
 RBC cell membrane changes: activate coagulation pathways
 Rate of polymerization and sickling augmented by:
 Hypoxia, deoxygenation
 Infections,
 Acidosis,
 Physical exercise,
 Vasoocclusion due to cold as well as hypertonic dehydration
feb,17,2015
14
Dr.ArmaanSingh
CLINICAL PRESENTATION
 Sickle cell trait (SCT) Carrier, recessive
 Rare painless hematuria; normal Hgb level; heavy exercise
under extreme conditions may provoke gross hematuria and
complications
 Sickle cell anemia (SCA)
 Anemia
 Chronic hemolytic anemia: jaundice, gall stone,
splenomegaly
 Acute Pain crises,
 Microvascular disruption of organs (spleen, liver, bone
marrow, kidney, brain, and lung), gallstone, priapism, leg
ulcers, anemia (Hgb 7-10 g/dL)
feb,17,2015
15
Dr.ArmaanSingh
CLINICAL PRESENTATION
 Sickle cell hemoglobin C:
 Painless hematuria
 Aseptic necrosis of bone: less common
 Vaso-occlusive crises less common, occur late in life
 Pregnancy-related problems; mild anemia (Hb 10–12 g/dL)
 Sickle cell β-thalassemia
 Rare crises; milder severity than sickle cell disease because of
production of HbA;
 Hb 10–14 g/dL with micro-cytosis
 Sickle cell Alfa-thalassemia or β0 Thalassemia
 No HbA production; severity similar to sickle cell anemia; Hb
7–10 g/dL with microcytosis
feb,17,2015
16
Dr.ArmaanSingh
DIAGNOSIS
 Laboratory findings
 RBC’s: 5-50 % sickled
 Low hemoglobin; 7-10%; HbA; 0%; HbS 85-98%
 Increased reticulocytes: 10-25%, platelet, and
leukocyte counts; and sickle forms on the peripheral
smear
 Routine neonatal screening programs: DNA from
fetal cell for mutation
feb,17,2015
17
Dr.ArmaanSingh
GOALS OF THERAPY
To reduce
Hospitalizations,
Complications,
Mortality
feb,17,2015
18
Dr.ArmaanSingh
TREATMENT
 GENERAL PRINCIPLES
 No Treatment for the primary disease
 Lifelong multidisciplinary care
 general measures,
 preventive strategies,
 treatment of complications and acute crises.
 Routine immunizations plus influenza, meningococcal,
and pneumococcal vaccinations.
 Prophylactic penicillin for children with sickle cell
disease until they are 5 years old.
 Penicillin V potassium, 125 mg orallytwice daily until 3 years of age
and then 250 mg twice daily,
 Benzathine penicillin, 600,000 units intramuscularly every 4 weeks.
 Folic acid, 1 mg daily, is recommended in adult
patients, pregnant women, and patients of all ages
with chronic hemolysis.
feb,17,2015
19
Dr.ArmaanSingh
FETAL HEMOGLOBIN STIMULATORS AND
OTHER STRATEGIES
 Hydroxyurea, a chemotherapeutic agent
 Stimulate HbF by stimulating erythropoiesis
 In patients with frequent painful episodes, severe symptomatic anemia, acute
chest syndrome, or other severe vasoocclusive complications.
 Butyrate and 5-aza-2-deoxycytidine.
 Chronic transfusion every 3 to 4 weeks The optimal duration is
unknown
 to prevent stroke and stroke recurrence in children.
 Maintain HbS of less than 30% of total hemoglobin..
 Risks include, hyperviscosity, viral transmission (requiring hepatitis A and B
vaccination), volume and iron overload, and transfusion reactions.
 Allogeneic hematopoietic stem cell transplantation
 The only therapy that is curative.
 Best candidates are
 younger than 16 years of age,
 With severe complications,
 Have HLA-matched donors.
 Risks: mortality, graft rejection, and secondary malignancies
feb,17,2015
20
Dr.ArmaanSingh
STEM CELLS IN THE TREATMENT OF
SCD
 Skin stem cells cure mice of sickle cell
anemia
 Success is proof that technique has
potential to cure disease
http://www.msnbc.msn.com/id/22136029/
feb,17,2015
21
Dr.ArmaanSingh
COMPLICATIONS
 Acute Chest Syndrome
 Septicemia
 Stroke or CVA
 Acute splenic sequestration crisis (ASSC)
 Aplastic Crisis
 VasoOcclusive pain: Sickle cell crisis
 Severe pain is an emergency called acute sickle
cell crisis
 Osteomyelitis
feb,17,2015
22
Dr.ArmaanSingh
SICKLE CELL CRISIS
 Rapid diagnosis and treatment are necessary to
minimize morbidity and mortality.
feb,17,2015
23
Dr.ArmaanSingh
CASE 1
 A 16-year-old boy with a history of SCD
presented to the ED with a 3-day history
of fever, cough, and SOB.
 Five days prior, he had been evaluated
and treated for severe pain in his legs and
arms.
 He complained of persistent and
worsening pain in both his lower
extremities and pain in his chest, in spite
of oral narcotic therapy.
feb,17,2015
24
Dr.ArmaanSingh
 His medical history included multiple, vasoocclusive,
painful crises, including an episode of priapism, and he
had received multiple blood transfusions over his
lifetime.
feb,17,2015
25
Dr.ArmaanSingh
Case 1
CASE -1
On examination
 Temp 39.1°C, diaphoretic, and uncomfortable.
 HR of 80, BP 116/84 mm Hg, RR 26
 O2 Sat 89% and improved to 94% with 6 L/min
via face mask.
 Conjunctivae were icteric
 Mucous membranes were moist
feb,17,2015
26
Dr.ArmaanSingh
 Cardiovascular II/VI systolic ejection
murmur.
 labored respiration with suprasternal and
intercostal retractions.
 decreased breath sounds in the right
midzone and lower zone, and scattered
crepitations on the right side.
 no lower extremity edema
 Abdominal examination Normal
 CNS Normal
feb,17,2015
27
Dr.ArmaanSingh
Case 1
 WBC of 17 500/μL
 62% neutrophils
 25% lymphocytes
 9% monocytes
 2% eosinophils
 1% basophils
 1% atypical lymphocytes.
 Hb was 8 g/dL
 reticulocyte 25%
 platelet 206 000/μL.
feb,17,2015
28
Dr.ArmaanSingh
ABG on room air
•PO2 59 mm Hg
•PCO2 29 mm Hg
•pH 7.32
•HCO3 13 mmol
A chest x-ray right lower-lobe consolidation
with a moderate right pleural effusion.
Case 1
 In the ED, he received
 antipyretics
 supplemental oxygen
 cefotaxime 2 g IV
 packed red blood cell transfusion was initiated after 20 mL/kg of
normal saline was infused
 Over the next hour, while waiting for a bed to become
available in the intensive care unit, the nurse noticed
that the patient's oxygen saturation continued to
worsen, and he was hypoxic even on supplemental
oxygen of 12 L/min via nonrebreather mask.
 He underwent emergency intubation
 A diagnostic pleural tap was performed which
demonstrated an exudative fluid.
 The resulting Gram stain and culture were negative.
feb,17,2015
29
Dr.ArmaanSingh
Case-1
CASE 1
What is it
feb,17,2015
30
Dr.ArmaanSingh
1.ACUTE CHEST SYNDROME
1 of the most serious and life-
threatening complications of SCD
Leading cause of mortality and
morbidity in affected patients, since the
impact of more effective antimicrobials
and the pneumococcal vaccine
Caused by a vasoocclusive crisis
involving the pulmonary vasculature.
Not distinguishable from pneumonia
feb,17,2015
31
Dr.ArmaanSingh
 New infiltrate on chest radiograph in combination
with at least 1 clinical sign or symptom
 Chest pain
 Cough
 Wheezing
 Tachypnea
 Fever
feb,17,2015
32
Dr.ArmaanSingh
•Fever and cough are the most common in
children
•chest pain, sob, and chills are common in
adults.
1.Acute Chest Syndrome
Dx
Common causes
Pulmonary infection:
Mycoplasma pneumoniae more
commonly associated with acute chest
syndrome
Thromboemboli
Fat emboli
Rib infarction
Infection and fat emboli were the most common
identifiable causes.
Vichinsky EP, Neumayr LD, Earles AN, et al. Causesand outcomes of the acute chest syndrome in sickle cell disease.
National Acute Chest Syndrome Study Group [published erratum appears in N Engl J Med 2000; 343:824]. N Engl J Med
2000;342:1855–65.
1.Acute Chest Syndrome
Possible causes
Iatrogenic:
excessive hydration
or
narcotic use
feb,17,2015Dr.ArmaanSingh
33
Therapeutic Modalities
 Supportive measures
 Oxygen for hypoxia
 Appropriate hydration
 Appropriate pain control
 Antibiotics: third-generation cephalosporin +
macrolides
 Transfusion therapy:
 Reports of dramatic improvement in clinical condition
after initiation of transfusion
 Simple transfusion
 Exchange transfusion
 Experimental therapy
 Nitric oxide
 Corticosteroids
feb,17,2015
34
Dr.ArmaanSingh
1.Acute Chest Syndrome
Bodo I, Khoury H, Blinder M. Rapid resolution of the acute chest syndrome of sickle cell disease after automated red cell exchange.
Blood 1997;90 Suppl 1:23b
2.SEPTICEMIA
 SCD pts have impaired immunologic function that is caused
by splenic dysfunction.
 Impairment of splenic function can occur in infants as young
as 3 months.
 High risk for encapsulated organisms such as S pneumoniae
and H influenzae.
 Recommended antibiotic
 Third-generation cephalosporin; ceftriaxone, or cefotaxime
 Vancomycin should be added to protect against penicillin-
resistant strains of S pneumoniae if suspected until culture
results become available
 All SCD patients with fever must be managed with extreme caution
because of the risk of overwhelming bacteremia which can rapidly
lead to septic shock

feb,17,2015
35
Dr.ArmaanSingh
3.STROKE OR CVA
 Major complication of SCD
 Is a leading cause of death in both and disability
children and adults
 The most common is blockage of the intracranial
internal carotid and middle cerebral arteries.
 Patients with stroke usually present with obvious
signs such as acute hemiparesis, aphasia or dysphasia,
seizures, severe headaches, cranial nerve palsy,
altered mental status, or coma.
 The most common tends to be hemiparesis.
 Can be very subtle, such as a slight limp
feb,17,2015
36
Dr.ArmaanSingh
TREATMENT: STROKE OR CVA
 Initial therapy is
 exchange transfusion in an ICU setting to reduce Hb
S to less than 30% of total Hb.
 After acute clearance of symptoms should be started
on a long-term transfusion therapy.
 If not on a long-term transfusion program have an 80%
chance of recurrent stroke within 3 years of the initial
event
 Long-term transfusion involves regularly scheduled
blood transfusions aimed at reducing the percentage of
Hb S and not at normalizing the Hb level.

feb,17,2015
37
Dr.ArmaanSingh
CASE 2
A 44-year-old diabetic presented to the ED complaining of nonexertional
dyspnea and severe back pain for 12 hours before presentation.
The patient reported malaise, fatigue, weakness that started 3 days before,
chronic blurred vision, insomnia, and anxiety.
The remainder of the review of systems was unremarkable.
feb,17,2015Dr.ArmaanSingh
38
 O/E
 HR 101 bpm
 RR 31/min
 Temp 37C
 BP 148/62 mm Hg
o2 sat 99%.
 The patient was awake, alert, and oriented
 He was motionless to avoid back pain.
feb,17,2015
39
Dr.ArmaanSingh
Case 2
 Normal S1 and S2
 Chest Normal
 Strength was 4/5 in all 4 extremities.
 Deep tendon reflexes were normoactive.
 Normal flexor plantar response was obtained, and no
meningismus
feb,17,2015
40
Dr.ArmaanSingh
Case 2
O/E
 WBC 11.2 × 109/L (with no abnormalities in
differential count)
 Hg of 9.4 g/dL
 HCT of 26.3%
 MCVof 76.7 Femtoliters (fL)
 MCH 27.3 pg
 Platelets of 144 × 109/L.
feb,17,2015
41
Dr.ArmaanSingh
Case 2
 Total bilirubin level of 2.3 mg/dl
 Direct bilirubin level of 0.8 mg/dL
 ESR 54 mm/h
 C-reactive protein level of 2.3 mg/dL.
 ECG Normal
 MRI of the lumbar spine was Normal
feb,17,2015
42
Dr.ArmaanSingh
• Blood glucose 267 mg/dL
• AST 79 U/L
• ALT 30 of U/L
• ALK Ph 475 U/L
Case 2
Despite aggressive narcotic treatment of back
pain, the pain continued to increase
CT abdomen: an enlarged spleen
1 hour later hypotension of 90/50 mm Hg.
The new CT scan of the abdomen revealed an
increasing splenomegaly compared with the
previous one
feb,17,2015
43
Dr.ArmaanSingh
Case 2
 Despite transfusion therapy, the patient's Hb
progressively dropped to a level of less than 4 mg/dL
over the course of 3 hours, with thrombocytopenia (<50
× 109/L).
 immediately transferred to an ICU.
 altered mental status.
 Airway protection with intubation and mechanical
ventilation were initiated.
 As the patient was rapidly deteriorating, an emergent
splenectomy was performed
 The patient recovered every organ function and, 6
months later, has resumed his normal activities
feb,17,2015
44
Dr.ArmaanSingh
Case 2
4.ACUTE SPLENIC SEQUESTRATION
CRISIS (ASSC)
 Clinical Presentation:
 Sudden impounding of red blood cells by the spleen
 Characterized by the rapid fall in hemoglobin concentration, rise in
reticulocyte count, and splenomegaly
 Requires prompt recognition and treatment.
 In the adult patient, ASSC is extremely rare.
 Hypotension caused by large volumes of blood (mainly sickled
cells) entrapped in the spleen.
 Hb levels may fall acutely more than 2 g/dL less than the patient's
normal value, causing circulatory compromise
 Treatment:
 Prompt diagnosis and therapy with RBC transfusions
 Surgical splenectomy may be indicated in certain patients to prevent
recurrences
feb,17,2015
45
Dr.ArmaanSingh
5.APLASTIC CRISIS
 Temporary cessation of red cell production with a
corresponding decrease in the reticulocyte count.
 Approximately 80%, are thought to be caused by human
parvovirus B19 infection
 Diagnosis is made by comparing baseline blood and
reticulocyte counts to those obtained during the acute
illness.
 Sign Symptoms: , tachypnea, tachycardia, or hypoxia
 Treatment:
 Simple blood transfusion to raise serum Hb back to the patient's
baseline and to prevent heart failure secondary to severe anemia.
 Parvovirus B19 is contagious, affected persons should be isolated
from pregnant women, who are at risk for miscarriage with
infection, and from immuno-compromised patients and those
with chronic illness
feb,17,2015
46
Dr.ArmaanSingh
6.OSTEOMYE
LITIS
 Most commonly caused by Salmonella species
or Staphylococcus aureus
 Bone pain or joint pain with localized swelling
and decreased range of motion, along with
fever, should alert the physician to the
possibility of osteomyelitis.
 Increased white blood cell count and elevated
ESR
 Broad-spectrum antibiotic:
Ceftriaxone:
feb,17,2015
47
Dr.ArmaanSingh
7.PRIAPISM
 Painful prolonged erection of the penis
 Caused by sickling of the red blood cells producing venous
stasis in the erectile tissue of the penis.
 The resulting stasis causes ischemia, hypoxia, and pain.
 Treatment:
 Initial treatment involves intravenous hydration and analgesia.
 Antianxiety agents
 Vasoconstrictors to force blood out of corpus cavernosum:
 Phenyl ephedrine
 Epinephrine
 Vasodilators: to relax smooth muscles:
 Terbutaline
 Hydrallazine
 Episodes refractory to this initial management include direct
irrigation of the corporeal bodies of the penis
feb,17,2015
48
Dr.ArmaanSingh
VASO-OCCLUSIVE PAIN
CRISIS
feb,17,2015Dr.ArmaanSingh
49
8.VASO-OCCLUSIVE PAIN CRISES:
SUMMARY
 Most common symptoms of SCD
 Severe pain
 Caused by sickle-shaped red blood cells trapped in small blood
vessels causing localized ischemia.
Triggered by
 Dehydration, fever, cold exposure, and emotional stress
 Therapy
 Intravenous/Oral hydration
 Pain management
 It is useful to assess pain in a standard manner using pain
measurement scales ……………..See next
 Causal Treatment: (treatment of the cause)
 Poloxamer 188 (Flocor) a surfactant returns RBCs to a non adhesive
state and blocks RBC aggregation to enhance blood flow in ischemic
areas
feb,17,2015
50
Dr.ArmaanSingh
PAIN SCALE
 0  –  Pain free.
 Mild Pain  – Nagging, annoying, but doesn't really interfere with daily
living activities.
 1  –  Pain is very mild, barely noticeable.  Most of the time you don't
think about it.
 2  –  Minor pain.  Annoying and may have occasional stronger
twinges. 
 3  –  Pain is noticeable and distracting, however, you can get used to
it and adapt.
 Moderate– Interferes significantly with daily living activities.
 4 – Moderate pain. If you are deeply involved in an activity, it can
be ignored for a period of time, but is still distracting.
 – Moderately strong pain. It can't be ignored for more than a few
minutes, but with effort you still can manage to work or participate in
some social activities.
 6 – Moderately strong pain that interferes with normal daily
activities. Difficulty concentrating.
feb,17,2015
51
Dr.ArmaanSingh
PAIN SCALE
 Severe Pain – Disabling; unable to perform daily living
activities.
 7 – Severe pain that dominates your senses and significantly
limits your ability to perform normal daily activities or
maintain social relationships. Interferes with sleep.
 8 – Intense pain. Physical activity is severely limited.
Conversing requires great effort.
 9-Excruciating pain. Unable to converse. Crying out and/or
moaning uncontrollably.
 10 – Unspeakable pain. Bedridden and possibly delirious.
Very few people will ever experience this level of pain
feb,17,2015
52
Dr.ArmaanSingh
PAIN MANAGEMENT
 Mild to moderate pain
 NSAID’s or acetaminophen.
 Moderate pain
 Weak opioid, such as codeine or hydrocodone.
 Severe pain
 IV opioid morphine, hydro-morphone, fentanyl, and methadone.
 Titrate to pain relief and then administer on a scheduled basis with
as-needed dosing for breakthrough pain.
 Patient-controlled analgesia can be used
 Avoid
 Meperidine should be avoided because accumulation of the normeperidine
metabolite can cause neurotoxicity, especially in patients with impaired renal
function
 Minimize dependence /addiction by :
 Aggressive pain control,
 Frequent monitoring,
 Tapering medication according to response
feb,17,2015
53
Dr.ArmaanSingh
Principles of pain management (WHO guidelines)
 Morphine is the preferred agent in treatment of sickle cell pain.
 Start by the mouth
 By the Clock:
 Regular analgesia (4-6 hourly) with breakthrough doses when needed
 By the ladder:
 Patients move up the ladder or may also move down the ladder if pain decreases.
 Individualized Therapy:
 Start with higher step for Patients presenting with moderate to severe pain.
 Some don’t tolerate oral medication, plan for alternative route.
 Consider non drug therapies. as well
 No standard dose of opioid - morphine from 5mg to 1000mg every four hours.
 With attention to detail:
 Total analgesia usage should be monitored every 24 hours,
 Breakthrough doses should be adjusted in line with changes to regular medication.
 New pain should be assessed promptly
 Patients should be informed of possible adverse drug effects.
feb, 17, 2015 Dr. Armaan Singh 54
feb, 17, 2015 Dr. Armaan Singh 55
When and how IV
REASSESS before starting IV opioids and ADJUST dose
frequently, but not before 8 hours
Scheduled IV Narcotic Dosing for 24 hours, round the
clock
Morphine sulfate: 0.1 mg/kg, 5 - 10mg, IV scheduled
every 3-4 hours.
Hydromorphone: 0.015 mg/kg, 0.75 - 2mg, IV scheduled
every 3-4 hours.
Monitor vital signs and pain level, using the pain scale,
before and after every dose
feb, 17, 2015 Dr. Armaan Singh 56
IV dosing: cares
Doses should be based on level of tolerance to
opioids. Most SCD patients have some opioid
tolerance.
Maximum analgesic effect within 10-15 minutes and
will usually last 2-3 hours.
 Consider around-the –clock (ATC) (patient may
refuse) to ensure the patient is offered the medication
consistently at the preferred interval.
feb, 17, 2015 Dr. Armaan Singh 57
Scheduled IV Narcotic Dosing -- Opiate Tolerant patients
Convert the patients usual oral dose to IV:
Morphine IV/PO ratio: 1:3
Hydromorphone IV/PO ratio: 1:5
 Example: Patient is taking morphine SR 60mg PO
q12h and is now in pain crisis, requiring an additional
10mg PO q4 hours. 10mg X 6 = 60 mg + (60 mg x 2) =
180 mg PO morphine/day.
 Convert PO to IV: 180mg PO / 3 = 60mg IV over 24h =
10mg IV q4h
 Start with 50-75% of the calculated equianalgesic dose
if changing / converting to a different opioid to allow
for incomplete cross-tolerance between opioids.
Dose adjustment for taper
Decrease dose by 25% per day once the patient’s pain is
under control for 24 hours
feb, 17, 2015 Dr. Armaan Singh 58
Monitoring the patient
Chest X-ray: Order for any patient with cardiopulmonary
complaints, hypoxia, know chronic lung disease, fever,
tachycardia, or tachypnea.
Complete blood count q24 hours
Comprehensive metabolic panel, magnesium,
phosphorous q48 hours
Keep magnesium level > 2 mg/dL:
Magnesium < 1.8 mg/dL, replace with IV magnesium
May need to follow with daily oral supplementation
Magnesium > 1.8 mg/dL, replace with oral product
Lactic dehydrogenase (LDH) q72 hours
feb, 17, 2015 Dr. Armaan Singh 59
PCA

Patient-controlled analgesia (PCA) is a method of
pain control that gives patients the power to control
their pain. In PCA, a computerized pump called the
patient-controlled analgesia pump, which contains a
syringe of pain medication as prescribed by a doctor,
is connected directly to a patient's intravenous (IV)
line.
feb, 17, 2015 Dr. Armaan Singh 60
Patient Controlled Analgesia (PCA)
For setting where scheduled IV dosing is not controlling the patient’s pain.
There is no “PCA protocol.”
Continuous opioid infusion
should not be used in opioid naive patients until assessed the needs over a
given period of time (i.e. after 12 hrs of demand/bolus doses)
Only use a in patients with a known opioid requirement.
Those patients taking daily opioids: calculate an equianalgesic dose of
currently used opioids over past 24 hrs and then convert to an
equianalgesic basal rate
Example: Patient taking 120 mg extended release morphine Q 12 hrs now
in crisis taking an additional 15 mg immediate release morphine q 4 hrs. 15
mg X 6 = 90 mg + (120 mg X 2)= 330 mg PO morphine/day. Convert to IV
equivalent 330/3= 110 mg IV morphine/24 hrs = 4-5 mg/hr.
If changing/converting to a different opioid, start with 50-75% of the
calculated equianalgesic dose to allow for incomplete cross-tolerance
between opioids.feb, 17, 2015 Dr. Armaan Singh 61
Titration of Dose
Basal infusions will take at least 8 hours to reach steady state.
Do not titrate the basal rate more frequently than every 8
hours.
Never increase basal rate by more than 100% at any one time.
Demand Doses: Adjust demand dose size every 30-60 minutes
to quickly reach adequate analgesia.
For mild-moderate pain increase dose by 25-50%.
For moderate-severe pain increase dose by 50-100%.
feb, 17, 2015 Dr. Armaan Singh 62
Converting IV to Oral Pain Management
Once the IV dose has been tapered to 50% of the
initial dose, start oral morphine or hydromorphone:
Morphine & Hydromorphone: Add total daily dose of
IV morphine received; multiply by 2-3 to determine
total daily dose.
Immediate release formulations should be
administered on a scheduled basis, every 4 hours.
Sustained release formulations should be
administered every 12 hours.
Morphine to oral Oxycodone:
Convert morphine 10mg IV q4h to oxycodone 30 mg PO
q6h.
feb, 17, 2015 Dr. Armaan Singh 63
Adjunct therapies
Bowel regimen: All patients on opioids must also be
on a bowel regimen of stool softener and a cathartic.
May administer Hydroxyzine 25-50 mg PO with each
narcotic dose.
Itching:
Diphenhydramine 50mg IV/PO can be given with the
initial dose of morphine and PRN
Diphenhydramine may be given in conjunction with
opiates for additive effect.
 Nausea: administer prochlorperazine 10mg PO PRN
nausea.
feb, 17, 2015 Dr. Armaan Singh 64
EVALUATION OF THERAPEUTIC
OUTCOMES
 All patients should be evaluated regularly to establish
change in baseline, parameters
 Laboratory evaluations
 complete blood cell and reticulocyte counts
 HbF level.
 Kidney and Liver function tests and pulmonary function
 Patients should be screened for retinopathy.
 The efficacy of hydroxyurea can be assessed by
monitoring the number, severity, and duration of
sickle cell crises.
feb,17,2015
65
Dr.ArmaanSingh

Sickle cell disease

  • 1.
    SICKLE CELL DISEASE & ITSCOMPLICATIONS (COMPLETE INFO. PPT) Dr. Armaan Singh
  • 2.
    CASE  A 20years old male reported with history of delayed puberty, decreased growth, severe joint pain, severe weakness and cough. He also have defective vision  Past history reveals episodes of jaundice, severe body aches and pains, and gall stones  In his childhood he used to have frequently fever swelling of the hands and feet and pain in the chest, abdomen, limbs, and joints and nosebleeds and frequent upper respiratory infections feb,17,2015 2 Dr.ArmaanSingh
  • 3.
    CASE  O/E; Decreasedgrowth, delayed signs of puberty severely anemic, mildly jaundiced, ulcers on right leg, inflamed gums  Enlarged spleen.  Temp 39.1°C, diaphoretic, and uncomfortable.  HR of 90, BP 116/84 mm Hg, RR 26  O2 Sat 89% and improved to 94% with 6 L/min via face mask.  Family history: similar problem in one of his cousin who died at the age of 30, who used to receive blood transfusions feb,17,2015 3 Dr.ArmaanSingh
  • 4.
    CASE  WBC of17 500/μL  62% neutrophils  25% lymphocytes  9% monocytes  2% eosinophils  1% basophils  1% atypical lymphocytes.  Hb was 8 g/dL  reticulocyte 25%  platelet 206 000/μL. feb,17,2015 4 Dr.ArmaanSingh
  • 5.
    CASE  Which labtest you will advise?  What is most probable cause of patients problem?  What complications the patient may have?  Design therapeutic objectives for this patient? feb,17,2015 5 Dr.ArmaanSingh
  • 6.
  • 7.
    HEMOGLOBIN: INTRODUCTION  Normal:alpha gene at Chr 16, beta at Chr.11  HbA: 2 Alfa + 2 beta97-98%  Hb A2: 2 Alfa + 2 delta 2-3%  Hb F; 2 alfa + 2 gamma >1%  Hb S: Glutamic acid at 6 in beta chain replaced with Valine  HbC: ……………………………………………………………………….Lysine  Thalassemia:  Thalassemia describes a group of inherited disorders characterized by reduced or absent amounts of hemoglobin  Alfa: less alfa chain Chr.16  Beta: Chr.11: less beta, beta thalassemia minor or no beta, all alfa chain beta thalassemia major : feb,17,2015 7 Dr.ArmaanSingh
  • 8.
     An autosomalrecessive genetic disease of Hb synthesis  Result of a single–amino acid substitution in the β- globin chain of the Hb molecule, valine for glutamate at position 6  Sickle cell trait: Pt. with hetrozygous genotype  Epidemiology in KSA:  “The prevalence of SCD in Saudi Arabia varies significantly in different parts of the country, with the highest prevalence is in the Eastern province, followed by the southwestern provinces. The reported prevalence for sickle-cell trait ranges from 2% to 27%, and up to 2.6% will have SCD in some areas”  Ann Saudi Med. 2011 May-Jun; 31(3): 289–293. feb,17,2015 8 Dr.ArmaanSingh SICKLE CELL DISEASE
  • 9.
    COMPARISON WITH USA African Americans:  SCD: 0.3% Saudia: 2.6%  SCT: 8.0% Saudia: 2-27% feb,17,2015 9 Dr.ArmaanSingh
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
    PATHOPHYSIOLOGY  Normal HemoglobinA: two alpha and two beta chains, 96-97%  Glutamic acid is on the 6th position of the Beta chain  Hemoglobin S: Chr.11  Due to a one point mutation, glutamic acid is replaced by valine at position 6 in beta chain  HbS: during deoxygenation  Polymerize  Crystellize  in RBC’s…………………….leading to………………….. Sickling of Cells:  RBC cell membrane changes: activate coagulation pathways  Rate of polymerization and sickling augmented by:  Hypoxia, deoxygenation  Infections,  Acidosis,  Physical exercise,  Vasoocclusion due to cold as well as hypertonic dehydration feb,17,2015 14 Dr.ArmaanSingh
  • 15.
    CLINICAL PRESENTATION  Sicklecell trait (SCT) Carrier, recessive  Rare painless hematuria; normal Hgb level; heavy exercise under extreme conditions may provoke gross hematuria and complications  Sickle cell anemia (SCA)  Anemia  Chronic hemolytic anemia: jaundice, gall stone, splenomegaly  Acute Pain crises,  Microvascular disruption of organs (spleen, liver, bone marrow, kidney, brain, and lung), gallstone, priapism, leg ulcers, anemia (Hgb 7-10 g/dL) feb,17,2015 15 Dr.ArmaanSingh
  • 16.
    CLINICAL PRESENTATION  Sicklecell hemoglobin C:  Painless hematuria  Aseptic necrosis of bone: less common  Vaso-occlusive crises less common, occur late in life  Pregnancy-related problems; mild anemia (Hb 10–12 g/dL)  Sickle cell β-thalassemia  Rare crises; milder severity than sickle cell disease because of production of HbA;  Hb 10–14 g/dL with micro-cytosis  Sickle cell Alfa-thalassemia or β0 Thalassemia  No HbA production; severity similar to sickle cell anemia; Hb 7–10 g/dL with microcytosis feb,17,2015 16 Dr.ArmaanSingh
  • 17.
    DIAGNOSIS  Laboratory findings RBC’s: 5-50 % sickled  Low hemoglobin; 7-10%; HbA; 0%; HbS 85-98%  Increased reticulocytes: 10-25%, platelet, and leukocyte counts; and sickle forms on the peripheral smear  Routine neonatal screening programs: DNA from fetal cell for mutation feb,17,2015 17 Dr.ArmaanSingh
  • 18.
    GOALS OF THERAPY Toreduce Hospitalizations, Complications, Mortality feb,17,2015 18 Dr.ArmaanSingh
  • 19.
    TREATMENT  GENERAL PRINCIPLES No Treatment for the primary disease  Lifelong multidisciplinary care  general measures,  preventive strategies,  treatment of complications and acute crises.  Routine immunizations plus influenza, meningococcal, and pneumococcal vaccinations.  Prophylactic penicillin for children with sickle cell disease until they are 5 years old.  Penicillin V potassium, 125 mg orallytwice daily until 3 years of age and then 250 mg twice daily,  Benzathine penicillin, 600,000 units intramuscularly every 4 weeks.  Folic acid, 1 mg daily, is recommended in adult patients, pregnant women, and patients of all ages with chronic hemolysis. feb,17,2015 19 Dr.ArmaanSingh
  • 20.
    FETAL HEMOGLOBIN STIMULATORSAND OTHER STRATEGIES  Hydroxyurea, a chemotherapeutic agent  Stimulate HbF by stimulating erythropoiesis  In patients with frequent painful episodes, severe symptomatic anemia, acute chest syndrome, or other severe vasoocclusive complications.  Butyrate and 5-aza-2-deoxycytidine.  Chronic transfusion every 3 to 4 weeks The optimal duration is unknown  to prevent stroke and stroke recurrence in children.  Maintain HbS of less than 30% of total hemoglobin..  Risks include, hyperviscosity, viral transmission (requiring hepatitis A and B vaccination), volume and iron overload, and transfusion reactions.  Allogeneic hematopoietic stem cell transplantation  The only therapy that is curative.  Best candidates are  younger than 16 years of age,  With severe complications,  Have HLA-matched donors.  Risks: mortality, graft rejection, and secondary malignancies feb,17,2015 20 Dr.ArmaanSingh
  • 21.
    STEM CELLS INTHE TREATMENT OF SCD  Skin stem cells cure mice of sickle cell anemia  Success is proof that technique has potential to cure disease http://www.msnbc.msn.com/id/22136029/ feb,17,2015 21 Dr.ArmaanSingh
  • 22.
    COMPLICATIONS  Acute ChestSyndrome  Septicemia  Stroke or CVA  Acute splenic sequestration crisis (ASSC)  Aplastic Crisis  VasoOcclusive pain: Sickle cell crisis  Severe pain is an emergency called acute sickle cell crisis  Osteomyelitis feb,17,2015 22 Dr.ArmaanSingh
  • 23.
    SICKLE CELL CRISIS Rapid diagnosis and treatment are necessary to minimize morbidity and mortality. feb,17,2015 23 Dr.ArmaanSingh
  • 24.
    CASE 1  A16-year-old boy with a history of SCD presented to the ED with a 3-day history of fever, cough, and SOB.  Five days prior, he had been evaluated and treated for severe pain in his legs and arms.  He complained of persistent and worsening pain in both his lower extremities and pain in his chest, in spite of oral narcotic therapy. feb,17,2015 24 Dr.ArmaanSingh
  • 25.
     His medicalhistory included multiple, vasoocclusive, painful crises, including an episode of priapism, and he had received multiple blood transfusions over his lifetime. feb,17,2015 25 Dr.ArmaanSingh Case 1
  • 26.
    CASE -1 On examination Temp 39.1°C, diaphoretic, and uncomfortable.  HR of 80, BP 116/84 mm Hg, RR 26  O2 Sat 89% and improved to 94% with 6 L/min via face mask.  Conjunctivae were icteric  Mucous membranes were moist feb,17,2015 26 Dr.ArmaanSingh
  • 27.
     Cardiovascular II/VIsystolic ejection murmur.  labored respiration with suprasternal and intercostal retractions.  decreased breath sounds in the right midzone and lower zone, and scattered crepitations on the right side.  no lower extremity edema  Abdominal examination Normal  CNS Normal feb,17,2015 27 Dr.ArmaanSingh Case 1
  • 28.
     WBC of17 500/μL  62% neutrophils  25% lymphocytes  9% monocytes  2% eosinophils  1% basophils  1% atypical lymphocytes.  Hb was 8 g/dL  reticulocyte 25%  platelet 206 000/μL. feb,17,2015 28 Dr.ArmaanSingh ABG on room air •PO2 59 mm Hg •PCO2 29 mm Hg •pH 7.32 •HCO3 13 mmol A chest x-ray right lower-lobe consolidation with a moderate right pleural effusion. Case 1
  • 29.
     In theED, he received  antipyretics  supplemental oxygen  cefotaxime 2 g IV  packed red blood cell transfusion was initiated after 20 mL/kg of normal saline was infused  Over the next hour, while waiting for a bed to become available in the intensive care unit, the nurse noticed that the patient's oxygen saturation continued to worsen, and he was hypoxic even on supplemental oxygen of 12 L/min via nonrebreather mask.  He underwent emergency intubation  A diagnostic pleural tap was performed which demonstrated an exudative fluid.  The resulting Gram stain and culture were negative. feb,17,2015 29 Dr.ArmaanSingh Case-1
  • 30.
    CASE 1 What isit feb,17,2015 30 Dr.ArmaanSingh
  • 31.
    1.ACUTE CHEST SYNDROME 1of the most serious and life- threatening complications of SCD Leading cause of mortality and morbidity in affected patients, since the impact of more effective antimicrobials and the pneumococcal vaccine Caused by a vasoocclusive crisis involving the pulmonary vasculature. Not distinguishable from pneumonia feb,17,2015 31 Dr.ArmaanSingh
  • 32.
     New infiltrateon chest radiograph in combination with at least 1 clinical sign or symptom  Chest pain  Cough  Wheezing  Tachypnea  Fever feb,17,2015 32 Dr.ArmaanSingh •Fever and cough are the most common in children •chest pain, sob, and chills are common in adults. 1.Acute Chest Syndrome Dx
  • 33.
    Common causes Pulmonary infection: Mycoplasmapneumoniae more commonly associated with acute chest syndrome Thromboemboli Fat emboli Rib infarction Infection and fat emboli were the most common identifiable causes. Vichinsky EP, Neumayr LD, Earles AN, et al. Causesand outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group [published erratum appears in N Engl J Med 2000; 343:824]. N Engl J Med 2000;342:1855–65. 1.Acute Chest Syndrome Possible causes Iatrogenic: excessive hydration or narcotic use feb,17,2015Dr.ArmaanSingh 33
  • 34.
    Therapeutic Modalities  Supportivemeasures  Oxygen for hypoxia  Appropriate hydration  Appropriate pain control  Antibiotics: third-generation cephalosporin + macrolides  Transfusion therapy:  Reports of dramatic improvement in clinical condition after initiation of transfusion  Simple transfusion  Exchange transfusion  Experimental therapy  Nitric oxide  Corticosteroids feb,17,2015 34 Dr.ArmaanSingh 1.Acute Chest Syndrome Bodo I, Khoury H, Blinder M. Rapid resolution of the acute chest syndrome of sickle cell disease after automated red cell exchange. Blood 1997;90 Suppl 1:23b
  • 35.
    2.SEPTICEMIA  SCD ptshave impaired immunologic function that is caused by splenic dysfunction.  Impairment of splenic function can occur in infants as young as 3 months.  High risk for encapsulated organisms such as S pneumoniae and H influenzae.  Recommended antibiotic  Third-generation cephalosporin; ceftriaxone, or cefotaxime  Vancomycin should be added to protect against penicillin- resistant strains of S pneumoniae if suspected until culture results become available  All SCD patients with fever must be managed with extreme caution because of the risk of overwhelming bacteremia which can rapidly lead to septic shock  feb,17,2015 35 Dr.ArmaanSingh
  • 36.
    3.STROKE OR CVA Major complication of SCD  Is a leading cause of death in both and disability children and adults  The most common is blockage of the intracranial internal carotid and middle cerebral arteries.  Patients with stroke usually present with obvious signs such as acute hemiparesis, aphasia or dysphasia, seizures, severe headaches, cranial nerve palsy, altered mental status, or coma.  The most common tends to be hemiparesis.  Can be very subtle, such as a slight limp feb,17,2015 36 Dr.ArmaanSingh
  • 37.
    TREATMENT: STROKE ORCVA  Initial therapy is  exchange transfusion in an ICU setting to reduce Hb S to less than 30% of total Hb.  After acute clearance of symptoms should be started on a long-term transfusion therapy.  If not on a long-term transfusion program have an 80% chance of recurrent stroke within 3 years of the initial event  Long-term transfusion involves regularly scheduled blood transfusions aimed at reducing the percentage of Hb S and not at normalizing the Hb level.  feb,17,2015 37 Dr.ArmaanSingh
  • 38.
    CASE 2 A 44-year-olddiabetic presented to the ED complaining of nonexertional dyspnea and severe back pain for 12 hours before presentation. The patient reported malaise, fatigue, weakness that started 3 days before, chronic blurred vision, insomnia, and anxiety. The remainder of the review of systems was unremarkable. feb,17,2015Dr.ArmaanSingh 38
  • 39.
     O/E  HR101 bpm  RR 31/min  Temp 37C  BP 148/62 mm Hg o2 sat 99%.  The patient was awake, alert, and oriented  He was motionless to avoid back pain. feb,17,2015 39 Dr.ArmaanSingh Case 2
  • 40.
     Normal S1and S2  Chest Normal  Strength was 4/5 in all 4 extremities.  Deep tendon reflexes were normoactive.  Normal flexor plantar response was obtained, and no meningismus feb,17,2015 40 Dr.ArmaanSingh Case 2 O/E
  • 41.
     WBC 11.2× 109/L (with no abnormalities in differential count)  Hg of 9.4 g/dL  HCT of 26.3%  MCVof 76.7 Femtoliters (fL)  MCH 27.3 pg  Platelets of 144 × 109/L. feb,17,2015 41 Dr.ArmaanSingh Case 2
  • 42.
     Total bilirubinlevel of 2.3 mg/dl  Direct bilirubin level of 0.8 mg/dL  ESR 54 mm/h  C-reactive protein level of 2.3 mg/dL.  ECG Normal  MRI of the lumbar spine was Normal feb,17,2015 42 Dr.ArmaanSingh • Blood glucose 267 mg/dL • AST 79 U/L • ALT 30 of U/L • ALK Ph 475 U/L Case 2
  • 43.
    Despite aggressive narcotictreatment of back pain, the pain continued to increase CT abdomen: an enlarged spleen 1 hour later hypotension of 90/50 mm Hg. The new CT scan of the abdomen revealed an increasing splenomegaly compared with the previous one feb,17,2015 43 Dr.ArmaanSingh Case 2
  • 44.
     Despite transfusiontherapy, the patient's Hb progressively dropped to a level of less than 4 mg/dL over the course of 3 hours, with thrombocytopenia (<50 × 109/L).  immediately transferred to an ICU.  altered mental status.  Airway protection with intubation and mechanical ventilation were initiated.  As the patient was rapidly deteriorating, an emergent splenectomy was performed  The patient recovered every organ function and, 6 months later, has resumed his normal activities feb,17,2015 44 Dr.ArmaanSingh Case 2
  • 45.
    4.ACUTE SPLENIC SEQUESTRATION CRISIS(ASSC)  Clinical Presentation:  Sudden impounding of red blood cells by the spleen  Characterized by the rapid fall in hemoglobin concentration, rise in reticulocyte count, and splenomegaly  Requires prompt recognition and treatment.  In the adult patient, ASSC is extremely rare.  Hypotension caused by large volumes of blood (mainly sickled cells) entrapped in the spleen.  Hb levels may fall acutely more than 2 g/dL less than the patient's normal value, causing circulatory compromise  Treatment:  Prompt diagnosis and therapy with RBC transfusions  Surgical splenectomy may be indicated in certain patients to prevent recurrences feb,17,2015 45 Dr.ArmaanSingh
  • 46.
    5.APLASTIC CRISIS  Temporarycessation of red cell production with a corresponding decrease in the reticulocyte count.  Approximately 80%, are thought to be caused by human parvovirus B19 infection  Diagnosis is made by comparing baseline blood and reticulocyte counts to those obtained during the acute illness.  Sign Symptoms: , tachypnea, tachycardia, or hypoxia  Treatment:  Simple blood transfusion to raise serum Hb back to the patient's baseline and to prevent heart failure secondary to severe anemia.  Parvovirus B19 is contagious, affected persons should be isolated from pregnant women, who are at risk for miscarriage with infection, and from immuno-compromised patients and those with chronic illness feb,17,2015 46 Dr.ArmaanSingh
  • 47.
    6.OSTEOMYE LITIS  Most commonlycaused by Salmonella species or Staphylococcus aureus  Bone pain or joint pain with localized swelling and decreased range of motion, along with fever, should alert the physician to the possibility of osteomyelitis.  Increased white blood cell count and elevated ESR  Broad-spectrum antibiotic: Ceftriaxone: feb,17,2015 47 Dr.ArmaanSingh
  • 48.
    7.PRIAPISM  Painful prolongederection of the penis  Caused by sickling of the red blood cells producing venous stasis in the erectile tissue of the penis.  The resulting stasis causes ischemia, hypoxia, and pain.  Treatment:  Initial treatment involves intravenous hydration and analgesia.  Antianxiety agents  Vasoconstrictors to force blood out of corpus cavernosum:  Phenyl ephedrine  Epinephrine  Vasodilators: to relax smooth muscles:  Terbutaline  Hydrallazine  Episodes refractory to this initial management include direct irrigation of the corporeal bodies of the penis feb,17,2015 48 Dr.ArmaanSingh
  • 49.
  • 50.
    8.VASO-OCCLUSIVE PAIN CRISES: SUMMARY Most common symptoms of SCD  Severe pain  Caused by sickle-shaped red blood cells trapped in small blood vessels causing localized ischemia. Triggered by  Dehydration, fever, cold exposure, and emotional stress  Therapy  Intravenous/Oral hydration  Pain management  It is useful to assess pain in a standard manner using pain measurement scales ……………..See next  Causal Treatment: (treatment of the cause)  Poloxamer 188 (Flocor) a surfactant returns RBCs to a non adhesive state and blocks RBC aggregation to enhance blood flow in ischemic areas feb,17,2015 50 Dr.ArmaanSingh
  • 51.
    PAIN SCALE  0  –  Painfree.  Mild Pain  – Nagging, annoying, but doesn't really interfere with daily living activities.  1  –  Pain is very mild, barely noticeable.  Most of the time you don't think about it.  2  –  Minor pain.  Annoying and may have occasional stronger twinges.   3  –  Pain is noticeable and distracting, however, you can get used to it and adapt.  Moderate– Interferes significantly with daily living activities.  4 – Moderate pain. If you are deeply involved in an activity, it can be ignored for a period of time, but is still distracting.  – Moderately strong pain. It can't be ignored for more than a few minutes, but with effort you still can manage to work or participate in some social activities.  6 – Moderately strong pain that interferes with normal daily activities. Difficulty concentrating. feb,17,2015 51 Dr.ArmaanSingh
  • 52.
    PAIN SCALE  SeverePain – Disabling; unable to perform daily living activities.  7 – Severe pain that dominates your senses and significantly limits your ability to perform normal daily activities or maintain social relationships. Interferes with sleep.  8 – Intense pain. Physical activity is severely limited. Conversing requires great effort.  9-Excruciating pain. Unable to converse. Crying out and/or moaning uncontrollably.  10 – Unspeakable pain. Bedridden and possibly delirious. Very few people will ever experience this level of pain feb,17,2015 52 Dr.ArmaanSingh
  • 53.
    PAIN MANAGEMENT  Mildto moderate pain  NSAID’s or acetaminophen.  Moderate pain  Weak opioid, such as codeine or hydrocodone.  Severe pain  IV opioid morphine, hydro-morphone, fentanyl, and methadone.  Titrate to pain relief and then administer on a scheduled basis with as-needed dosing for breakthrough pain.  Patient-controlled analgesia can be used  Avoid  Meperidine should be avoided because accumulation of the normeperidine metabolite can cause neurotoxicity, especially in patients with impaired renal function  Minimize dependence /addiction by :  Aggressive pain control,  Frequent monitoring,  Tapering medication according to response feb,17,2015 53 Dr.ArmaanSingh
  • 54.
    Principles of painmanagement (WHO guidelines)  Morphine is the preferred agent in treatment of sickle cell pain.  Start by the mouth  By the Clock:  Regular analgesia (4-6 hourly) with breakthrough doses when needed  By the ladder:  Patients move up the ladder or may also move down the ladder if pain decreases.  Individualized Therapy:  Start with higher step for Patients presenting with moderate to severe pain.  Some don’t tolerate oral medication, plan for alternative route.  Consider non drug therapies. as well  No standard dose of opioid - morphine from 5mg to 1000mg every four hours.  With attention to detail:  Total analgesia usage should be monitored every 24 hours,  Breakthrough doses should be adjusted in line with changes to regular medication.  New pain should be assessed promptly  Patients should be informed of possible adverse drug effects. feb, 17, 2015 Dr. Armaan Singh 54
  • 55.
    feb, 17, 2015Dr. Armaan Singh 55
  • 56.
    When and howIV REASSESS before starting IV opioids and ADJUST dose frequently, but not before 8 hours Scheduled IV Narcotic Dosing for 24 hours, round the clock Morphine sulfate: 0.1 mg/kg, 5 - 10mg, IV scheduled every 3-4 hours. Hydromorphone: 0.015 mg/kg, 0.75 - 2mg, IV scheduled every 3-4 hours. Monitor vital signs and pain level, using the pain scale, before and after every dose feb, 17, 2015 Dr. Armaan Singh 56
  • 57.
    IV dosing: cares Dosesshould be based on level of tolerance to opioids. Most SCD patients have some opioid tolerance. Maximum analgesic effect within 10-15 minutes and will usually last 2-3 hours.  Consider around-the –clock (ATC) (patient may refuse) to ensure the patient is offered the medication consistently at the preferred interval. feb, 17, 2015 Dr. Armaan Singh 57
  • 58.
    Scheduled IV NarcoticDosing -- Opiate Tolerant patients Convert the patients usual oral dose to IV: Morphine IV/PO ratio: 1:3 Hydromorphone IV/PO ratio: 1:5  Example: Patient is taking morphine SR 60mg PO q12h and is now in pain crisis, requiring an additional 10mg PO q4 hours. 10mg X 6 = 60 mg + (60 mg x 2) = 180 mg PO morphine/day.  Convert PO to IV: 180mg PO / 3 = 60mg IV over 24h = 10mg IV q4h  Start with 50-75% of the calculated equianalgesic dose if changing / converting to a different opioid to allow for incomplete cross-tolerance between opioids. Dose adjustment for taper Decrease dose by 25% per day once the patient’s pain is under control for 24 hours feb, 17, 2015 Dr. Armaan Singh 58
  • 59.
    Monitoring the patient ChestX-ray: Order for any patient with cardiopulmonary complaints, hypoxia, know chronic lung disease, fever, tachycardia, or tachypnea. Complete blood count q24 hours Comprehensive metabolic panel, magnesium, phosphorous q48 hours Keep magnesium level > 2 mg/dL: Magnesium < 1.8 mg/dL, replace with IV magnesium May need to follow with daily oral supplementation Magnesium > 1.8 mg/dL, replace with oral product Lactic dehydrogenase (LDH) q72 hours feb, 17, 2015 Dr. Armaan Singh 59
  • 60.
    PCA  Patient-controlled analgesia (PCA)is a method of pain control that gives patients the power to control their pain. In PCA, a computerized pump called the patient-controlled analgesia pump, which contains a syringe of pain medication as prescribed by a doctor, is connected directly to a patient's intravenous (IV) line. feb, 17, 2015 Dr. Armaan Singh 60
  • 61.
    Patient Controlled Analgesia(PCA) For setting where scheduled IV dosing is not controlling the patient’s pain. There is no “PCA protocol.” Continuous opioid infusion should not be used in opioid naive patients until assessed the needs over a given period of time (i.e. after 12 hrs of demand/bolus doses) Only use a in patients with a known opioid requirement. Those patients taking daily opioids: calculate an equianalgesic dose of currently used opioids over past 24 hrs and then convert to an equianalgesic basal rate Example: Patient taking 120 mg extended release morphine Q 12 hrs now in crisis taking an additional 15 mg immediate release morphine q 4 hrs. 15 mg X 6 = 90 mg + (120 mg X 2)= 330 mg PO morphine/day. Convert to IV equivalent 330/3= 110 mg IV morphine/24 hrs = 4-5 mg/hr. If changing/converting to a different opioid, start with 50-75% of the calculated equianalgesic dose to allow for incomplete cross-tolerance between opioids.feb, 17, 2015 Dr. Armaan Singh 61
  • 62.
    Titration of Dose Basalinfusions will take at least 8 hours to reach steady state. Do not titrate the basal rate more frequently than every 8 hours. Never increase basal rate by more than 100% at any one time. Demand Doses: Adjust demand dose size every 30-60 minutes to quickly reach adequate analgesia. For mild-moderate pain increase dose by 25-50%. For moderate-severe pain increase dose by 50-100%. feb, 17, 2015 Dr. Armaan Singh 62
  • 63.
    Converting IV toOral Pain Management Once the IV dose has been tapered to 50% of the initial dose, start oral morphine or hydromorphone: Morphine & Hydromorphone: Add total daily dose of IV morphine received; multiply by 2-3 to determine total daily dose. Immediate release formulations should be administered on a scheduled basis, every 4 hours. Sustained release formulations should be administered every 12 hours. Morphine to oral Oxycodone: Convert morphine 10mg IV q4h to oxycodone 30 mg PO q6h. feb, 17, 2015 Dr. Armaan Singh 63
  • 64.
    Adjunct therapies Bowel regimen:All patients on opioids must also be on a bowel regimen of stool softener and a cathartic. May administer Hydroxyzine 25-50 mg PO with each narcotic dose. Itching: Diphenhydramine 50mg IV/PO can be given with the initial dose of morphine and PRN Diphenhydramine may be given in conjunction with opiates for additive effect.  Nausea: administer prochlorperazine 10mg PO PRN nausea. feb, 17, 2015 Dr. Armaan Singh 64
  • 65.
    EVALUATION OF THERAPEUTIC OUTCOMES All patients should be evaluated regularly to establish change in baseline, parameters  Laboratory evaluations  complete blood cell and reticulocyte counts  HbF level.  Kidney and Liver function tests and pulmonary function  Patients should be screened for retinopathy.  The efficacy of hydroxyurea can be assessed by monitoring the number, severity, and duration of sickle cell crises. feb,17,2015 65 Dr.ArmaanSingh